Literature DB >> 19553387

Regional distribution of clomipramine and desmethylclomipramine in rat brain and peripheral organs on chronic clomipramine administration.

K Aitchison1, K Datla, H Rooprai, J Fernando, D Dexter.   

Abstract

The tricyclic antidepressant (TCA) clomipramine has been widely used in psychiatry for over 40 years. More recently, its therapeutic potential as an antineoplastic drug has been identified. However, there are no prior data on regional distribution in the brain of clomipramine and its primary metabolite (desmethylclomipramine) after chronic oral administration. The aim of this study was to determine the concentrations of clomipramine and desmethylclomipramine in different rat-brain regions and to compare those with levels in plasma and peripheral organs after chronic oral treatment of Sprague Dawley rats (15 mg/kg) for 14 days. The levels of both parent TCA and metabolite were analysed by high-performance liquid chromatography in six brain regions (cortex, hypothalamus, hippocampus, striatum, brainstem and cerebellum), five peripheral organs and in plasma. Our data show that the cerebral cortex had the highest concentration of clomipramine (2.9 microg/mg), with successively lower concentrations in the hypothalamus, striatum, cerebellum, hippocampus and brainstem. Of the peripheral organs, the lungs and liver, had the highest levels of clomipramine, while in the heart, only the metabolite was detected. The plasma concentration (0.17 microg/ml or 0.48 microM) was comparable to that in the hippocampus and cerebellum (approximately 0.20 microg/mg). The differential distribution of clomipramine in different brain regions and the regional variation in clomipramine to desmethylclomipramine ratios have implications for the use of clomipramine in psychiatry and neuro-oncology.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19553387     DOI: 10.1177/0269881109105789

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  7 in total

1.  NET occupancy by clomipramine and its active metabolite, desmethylclomipramine, in non-human primates in vivo.

Authors:  Akihiro Takano; Sangram Nag; Balázs Gulyás; Christer Halldin; Lars Farde
Journal:  Psychopharmacology (Berl)       Date:  2011-02-19       Impact factor: 4.530

2.  Clomipramine treatment and repeated restraint stress alter parameters of oxidative stress in brain regions of male rats.

Authors:  Rodrigo de Souza Balk; Jessika Cristina Bridi; Rafael de Lima Portella; Nelson Rodrigues Carvalho; Fernando Dobrachinski; Michele Hinerasky da Silva; Guilherme Pires Amaral; Glaecir Roseni Mundstock Dias; Nilda de Vargas Barbosa; Felix Alexandre Antunes Soares
Journal:  Neurochem Res       Date:  2010-08-08       Impact factor: 3.996

3.  Association of tardive dyskinesia with variation in CYP2D6: Is there a role for active metabolites?

Authors:  Maju M Koola; Evangelia M Tsapakis; Padraig Wright; Shubulade Smith; Robert W Kerwin Rip; Katie L Nugent; Katherine J Aitchison
Journal:  J Psychopharmacol       Date:  2014-03-04       Impact factor: 4.153

4.  Intravenous lipid emulsion therapy for acute clomipramine intoxication in rats.

Authors:  Takumi Tsuji; Yuji Hattori; Koji Komori; Yuya Yoshida; Rie Banno; Takeyuki Kohno
Journal:  Acute Med Surg       Date:  2018-05-17

5.  The tricyclic antidepressant clomipramine inhibits neuronal autophagic flux.

Authors:  Federica Cavaliere; Alessandra Fornarelli; Fabio Bertan; Rossella Russo; Anaïs Marsal-Cots; Luigi Antonio Morrone; Annagrazia Adornetto; Maria Tiziana Corasaniti; Daniele Bano; Giacinto Bagetta; Pierluigi Nicotera
Journal:  Sci Rep       Date:  2019-03-19       Impact factor: 4.379

6.  In Vitro and In Vivo Pipeline for Validation of Disease-Modifying Effects of Systems Biology-Derived Network Treatments for Traumatic Brain Injury-Lessons Learned.

Authors:  Anssi Lipponen; Teemu Natunen; Mika Hujo; Robert Ciszek; Elina Hämäläinen; Jussi Tohka; Mikko Hiltunen; Jussi Paananen; David Poulsen; Emilia Kansanen; Xavier Ekolle Ndode-Ekane; Anna-Liisa Levonen; Asla Pitkänen
Journal:  Int J Mol Sci       Date:  2019-10-29       Impact factor: 5.923

Review 7.  Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far Have We Got and Where Are We Going?

Authors:  Roos van Westrhenen; Katherine J Aitchison; Magnus Ingelman-Sundberg; Marin M Jukić
Journal:  Front Psychiatry       Date:  2020-03-12       Impact factor: 4.157

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.